Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269
Debt
Debt-to-Equity RatioN/A
Current Ratio20.92
Quick Ratio20.93
Price-To-Earnings
Trailing P/E Ratio-3.62
Forward P/E Ratio-3.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.85 million
Price / Sales156.22
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.13
Profitability
EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,957.63%
Return on Equity-30.61%
Return on Assets-28.60%
Miscellaneous
Employees78
Outstanding Shares62,690,000
Market Cap$315.98 million
Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions
What is Adverum Biotechnologies' stock symbol?
Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."
How were Adverum Biotechnologies' earnings last quarter?
Adverum Biotechnologies Inc (NASDAQ:ADVM) issued its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.01. The biotechnology company earned $0.49 million during the quarter, compared to the consensus estimate of $0.40 million. Adverum Biotechnologies had a negative net margin of 3,957.63% and a negative return on equity of 30.61%. View Adverum Biotechnologies' Earnings History.
When is Adverum Biotechnologies' next earnings date?
What price target have analysts set for ADVM?
4 brokerages have issued 1 year price targets for Adverum Biotechnologies' shares. Their predictions range from $8.00 to $12.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $10.75 in the next year. This suggests a possible upside of 128.7% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.
What is the consensus analysts' recommendation for Adverum Biotechnologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adverum Biotechnologies.
Who are some of Adverum Biotechnologies' key competitors?
Some companies that are related to Adverum Biotechnologies include Solid Biosciences (SLDB), Momenta Pharmaceuticals (MNTA), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Audentes Therapeutics (BOLD), Iovance Biotherapeutics (IOVA), Acorda Therapeutics (ACOR), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Fate Therapeutics (FATE) and Heska (HSKA).
Who are Adverum Biotechnologies' key executives?
Adverum Biotechnologies' management team includes the folowing people:
- Dr. Mitchell H. Finer, Co-Founder & Director (Age 59)
- Dr. Mehdi Gasmi, Chief Science & Technology Officer (Age 51)
- Dr. Amber Salzman, Consultant (Age 56)
- Ms. Leone D. Patterson, Interim Pres, CEO, Sr. VP & CFO (Age 55)
- Ms. Katherine Bock, VP of Investor Relations and Corp. Communications
How do I buy shares of Adverum Biotechnologies?
Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adverum Biotechnologies' stock price today?
One share of ADVM stock can currently be purchased for approximately $4.70.
How big of a company is Adverum Biotechnologies?
Adverum Biotechnologies has a market capitalization of $315.98 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.
What is Adverum Biotechnologies' official website?
How can I contact Adverum Biotechnologies?
Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]
MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
